Table 3.
The volume of tumor and anti- tumor rate.
| Group | Volume (mm3) | The anti-tumor rate of 25d (%) | |||||
|---|---|---|---|---|---|---|---|
| 15d | 17d | 19d | 21d | 23d | 25d | ||
| Control | 107.99 ± 16 | 295.82 ± 40 | 670.61 ± 104 | 1031.86 ± 165 | 1252.45 ± 259 | 1441.46 ± 249 | — |
| Anti-EGFR- CIL-pWPXL | 103.74 ± 32 | 310.13 ± 148.13 | 598.15 ± 235 | 1014.98 ± 254 | 1319.15 ± 319.16 | 1634.39 ± 243 | −0.13 |
| pWPXL-miR- 135a | 105.6 ± 17 | 179.9 ± 72.05 | 423.98 ± 137.02 | 643.6 ± 195.36 | 1002.03 ± 225 | 1320.35 ± 217 | 0.08 |
| LCL-miR- 135a | 105.94 ± 21 | 213.84 ± 80 | 440.28 ± 176 | 531.18 ± 189.59 | 661.97 ± 180 | 754.68 ± 209 | 0.48 |
| Anti-EGFR- CIL-miR-135a | 117.18 ± 23 | 187.28 ± 60.31 | 305.5 ± 107 | 400.16 ± 155 | 512.9 ± 171 | 574.97 ± 184 | 0.60 |
Tumour volumes in mice bearing GBC xenografts on days 15, 17, 19, 21, 23, and 25 after inoculation and anti-tumour rates on day 25 after inoculation. Data are expressed as the mean ± SD (n = 8).